Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Spirogen has signed a research and licensing pact with a member of the Roche Group, Genentech to discover and develop antibody drug conjugates (ADC) as potential anticancer agents employing Spirogen's PBD drugs and associated linker technology.
Subscribe to our email newsletter
As per the agreement, Spirogen will take the responsibility to manufacture and synthesize drug reagents to generate ADCs and investigate their potential therapeutic utility.
Genentech will have the exclusive license for the development and commercialization of licensed products that contain these ADCs.
Terms of the multi-year collaboration include an initial one-off license fee, development milestones on reaching pre-defined targets and further milestones and royalties for licensed products.
Spirogen CEO Christopher Martin said that they are hopeful that this collaboration with Genentech will allow them to accelerate the development of ADCs based on the PBD drugs.
Genentech Partnering vice president James Sabry said that they believe ADCs have the potential to meaningfully impact the treatment of cancer.